NasdaqCM - Delayed Quote • USD
X4 Pharmaceuticals, Inc. (XFOR)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.16 | -0.04 | -0.45 | -0.45 |
| Low Estimate | -0.22 | -0.2 | -0.75 | -0.64 |
| High Estimate | -0.13 | 0.36 | -0.08 | -0.07 |
| Year Ago EPS | -0.16 | -0.33 | -0.57 | -0.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 7 |
| Avg. Estimate | -- | 510k | 14.19M | 59.15M |
| Low Estimate | -- | -- | 1.38M | 4.27M |
| High Estimate | -- | 1.99M | 54.63M | 163.1M |
| Year Ago Sales | -- | -- | -- | 14.19M |
| Sales Growth (year/est) | -- | -- | -- | 316.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.22 | -0.16 | -0.15 | -0.15 |
| EPS Actual | -0.16 | -0.33 | -0.01 | -0.1 |
| Difference | 0.06 | -0.17 | 0.14 | 0.05 |
| Surprise % | 27.30% | -106.20% | 93.30% | 33.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.04 | -0.45 | -0.45 |
| 7 Days Ago | -0.16 | -0.04 | -0.45 | -0.45 |
| 30 Days Ago | -0.15 | -0.01 | -0.45 | -0.46 |
| 60 Days Ago | -0.16 | -0.04 | -0.45 | -0.34 |
| 90 Days Ago | -0.16 | -0.04 | -0.45 | -0.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | XFOR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 6.50% |
| Next Qtr. | 87.90% | -- | -- | 12.00% |
| Current Year | 21.10% | -- | -- | 5.30% |
| Next Year | 0.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Downgrade | B. Riley Securities: Buy to Neutral | 12/12/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
| Maintains | Stifel: Buy to Buy | 5/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/5/2023 |
| Maintains | B. Riley Securities: Buy | 4/10/2023 |
Related Tickers
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
PDSB PDS Biotechnology Corporation
3.2700
+0.31%
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
EFTR eFFECTOR Therapeutics, Inc.
1.8900
+4.42%
MREO Mereo BioPharma Group plc
2.7400
-2.49%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
HOOK HOOKIPA Pharma Inc.
0.8933
+10.82%
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%